Studieoverzicht

Study name: Amgen Tarlatamab - Dellphi304

Histology SCLC
Tumor stage Stage IV
Host / recruiting sites LUMC
Enrollment Closed
Therapy line Later line (≥2L)
Design

Open label, gerandomiseerde fase 3 studie

Intervention

Tarlatamab vs Topotecan

Key outcome parameters

Primaire eindpunt: OS

Key inclusion criteria

Histologisch of cytologisch bevestigd relapse SCLC na 1 lijn platinum-bevattend regime

Key exclusion criteria

Onbehandelde of symptomatische CNS metastasen of leptomeningeale metastasen

Contact information